Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 10.89M |
| Revenue (ttm) | n/a |
| Net Income | -16.10M |
| EPS | -4.66 |
| Shares Out | 7.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,766 |
| Open | 1.510 |
| Previous Close | 1.510 |
| Day's Range | 1.510 - 1.550 |
| 52-Week Range | 1.232 - 15.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Financial Performance
Financial StatementsNews
Regentis Biomaterials reports ‘strong’ surgeon interest in GelrinC
Regentis Biomaterials (RGNT) announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists who visited the Company’s booth at the 8th International Car...
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technology GelrinC is CE Mark approved in Europe, wher...
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair so...
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce t...
Regentis Biomaterials reports 1H EPS (44c) vs. ($1.17) last year
“During the first half of 2026, we continued to advance GelrinC on multiple fronts as we build toward important clinical and commercial milestones in the U.S. and Europe,” said Ehud…
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon training...
Regentis announces Japan Patent Office issued Notice of Allowance
Regentis Biomaterials (RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for the Company’s patent application titled “Organic Solvent Free Compositions Comprising Protein-P...
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need f...
Regentis receives European regulatory approval for new GelrinC manufacturing
Regentis Biomaterials (RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. The approval comes ...
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®,...
Regentis Biomaterials registers to sell 3.81M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.81M ordinary shares. The company is not selling any shares under…
Regentis Biomaterials prices $6.5M private placement at $3.50 per share
Regentis Biomaterials (RGNT) “announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or ...
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solu...
Regentis Biomaterials Ltd trading resumes
10:38 EDT Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, volatility trading pause
10:25 EDT Regentis Biomaterials (RGNT) Ltd trading halted, volatility trading pause
Why Is Regentis Biomaterials Stock (RGNT) Up Today?
Regentis Biomaterials stock was up after the company withdrew an share offering.
Regentis Biomaterials Ltd trading resumes
12:25 EDT Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, news pending
11:41 EDT Regentis Biomaterials (RGNT) Ltd trading halted, news pending
Regentis Biomaterials to commence European surgeon training for GelrinC
Regentis Biomaterials (RGNT) announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout...
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of ...
Regentis Biomaterials enters collaboration with Humanitas Research Hospital
Regentis Biomaterials (RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy,. This collaboration is currently in the process of being formalized, is expected to support the...
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellenc...
Regentis Biomaterials develops and patents solvent-free manufacturing process
Regentis Biomaterials (RGNT) has developed a new manufacturing process for its lead product, GelrinC, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful...
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is pending...
Regentis Biomaterials initiated with a Buy at ThinkEquity
ThinkEquity initiated coverage of Regentis Biomaterials (RGNT) with a Buy rating and $10 price target Regentis is a single-asset medtech company advancing GelrinC for focal knee cartilage defects, the...